Diligence memo · auto-generated · as of July 2, 2026

Phytest Diagnostics, LLC

Phytest Diagnostics, LLC looks fair against its niche peers and is at-risk on financing cadence.

WatchOverdue for a raise versus sector cadence — could be a bridge, a down round, or distress. Watch for the next filing.

Businessfiled

Phytest Diagnostics, LLC operates in Pharmaceuticals, based in ATLANTA.

Sub-sector tags: medical-devices.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Phytest Diagnostics, LLC has raised $330K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $330K on 2023-08-01.

Most recent recorded round closed around 2023-08-01.

Valuation (modeled)modeled

Provath models Phytest Diagnostics, LLC at approximately $2.6M (range $185K–$11M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.00× the median modeled value of Pre-Seed Pharmaceuticals companies in 2022–2024 (38 peers) — value vs value, same stage and era. Within the normal band (100% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 2.9 yr ago; this sector typically re-raises about every 13 months.

Past due for a raise versus sector cadence — watch for distress or a bridge.

Comparablesmixed

Capital scale ranks ahead of 8% of Pharmaceuticals peers (1610 compared).

Modeled value ranks above 5% of those peers.

Closest niche peers: Eleison Pharmaceuticals Inc, Telomir Pharmaceuticals, Inc., Drusolv Therapeutics, Inc., TF Tech Ventures, Inc., Thyron Pharmaceuticals, Inc..

Peoplefiled

2 named people on file across officers, directors and signatories.

Risks & flagsmixed

Overdue for a raise versus sector norm — distress or bridge risk.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.